A Phase III trial found Velcade to be more effective than dexamethasone in treating relapsed multiple myeloma, with a 58% increase in efficacy. The study showed improved survival and reduced time to disease progression for patients receiving Velcade.
A recent study found that lung cancer patients in Japan had a longer median survival time (12 months) compared to US patients (9 months), despite receiving a lower dose of the same chemotherapy regimen. However, Japanese patients experienced more side effects, such as neutropenia and neuropathy.
Researchers have found a novel agent, SU11248, to be highly effective in treating advanced renal cell carcinoma. The treatment has shown significant activity in patients whose cancer had failed to respond to standard therapy.
A multicenter trial demonstrated that Taxotere in combination with cisplatin and 5-FU prolonged progression-free survival by 12.7 months compared to the standard treatment. Patients also showed significantly improved overall response rates, indicating a potential new paradigm for treating head and neck cancer.
Researchers at UC Davis Cancer Center discovered that sequential administration of erlotinib and docetaxel enhances effectiveness in treating non-small cell lung cancer. The study showed that giving docetaxel first, then erlotinib, was more effective than simultaneous or alternative administration.
A new sequential dose-dense chemotherapy regimen including ELLENCE significantly improves survival in high-risk breast cancer patients, with estimated 3-year relapse-free and overall survival rates of 80% and 90%, respectively. The study confirms the benefits of this optimal dose dense therapy for women at highest risk of recurrence.
The study found that Tarceva significantly improved overall survival and progression-free survival in patients with advanced NSCLC, with a median survival of 6.7 months compared to 4.7 months in the placebo arm. The treatment also showed improvements in time to symptom deterioration, response rate, and patient survival at one year.
A new breast cancer treatment, gemcitabine with paclitaxel, has been shown to extend overall survival in women with advanced breast cancer. The study found that median overall survival was 18.5 months for the combination therapy, compared to 15.8 months for paclitaxel alone.
A new medication called atrasentan has shown promise in slowing the progression of prostate cancer to the bone, reducing pain and maintaining quality of life. The drug's effect on stabilizing disease progression was observed across phase II and III clinical trials.
A study of 494 cancer patients found that specific genetic variants are associated with increased fatigue and distress, suggesting a possible link between genetics and quality of life in cancer patients. The research aims to develop personalized treatments tailored to an individual's genetic profile to improve their quality of life.
A Phase I/II trial combining bevacizumab (Avastin) and erlotinib (Tarceva) achieved 85% tumor control and 12.5-month median survival in advanced non-small cell lung cancer patients, outperforming traditional therapies.
Researchers at Fox Chase Cancer Center have discovered genetic markers that can predict how well patients with colorectal cancer will respond to certain chemotherapy drugs. The study found that variations in genes involved in metabolizing irinotecan may be useful predictors of response and side effects.
Researchers found that women with a specific gene mutation in the CYP2D6 gene had lower levels of endoxifen, a byproduct of tamoxifen metabolism. This suggests that the gene mutation may affect the potency of tamoxifen when combined with certain antidepressants like paroxetine and sertraline.
A novel therapeutic bortezomib combination will be tested in a phase II trial for advanced non-small cell lung cancer. The regimen, combining bortezomib with gemcitabine and carboplatin, shows promise in preclinical research, where giving bortezomib last may enhance its effectiveness.
A Phase II clinical trial suggests that RAD001, targeting mTOR, can decrease uterine tumor size in recurrent endometrial cancer. The treatment offers new hope for patients with advanced and recurrent cases, which account for about 7,000 deaths annually.
Researchers found that African Americans with NSCLC were less likely to receive staging procedures, which led to fewer surgical interventions. Despite equivalent survival rates among those who underwent surgery, African Americans were more likely to decline surgery when recommended.
The BP Conservation Programme is awarding $600,000 to 29 student-led teams for critical conservation projects worldwide. Winners will attend practical workshops and learn from global experts to carry out their projects.
Cohen's team found that fibroblast activation protein (FAP) and focal adhesion kinase (FAK) are overexpressed in over 90% of pancreatic adenocarcinomas, suggesting they may contribute to poor outcomes. However, selective inhibition of these proteins shows promise in preclinical models.
A new investigational drug has shown promise in treating kidney cancer, producing durable responses and stable disease in patients. The study found that nearly two-thirds of patients experienced stable disease after 12 weeks, and the median time to progression was nearly one year.